Lansoprazol Al

Lansoprazole, the active ingredient in Lansoprazol Al, is a proton pump inhibitor presented as an oral dosage form for oral use. By selectively inhibiting the gastric H+/K+ ATPase, it markedly reduces gastric acid secretion, providing symptomatic relief and promoting healing in acid‑related gastrointestinal conditions such as reflux disease and ulcers in adult patients.

GNH USA supplies Lansoprazol Al as a licensed, GDP‑compliant international pharmaceutical supplier, delivering bulk pharmaceutical material to hospitals, pharmacies, and clinics worldwide, with adherence to stringent quality and regulatory standards.

Lansoprazole is used to treat several acid‑related gastrointestinal disorders by suppressing gastric acid production. - Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes esophageal healing. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.

Lansoprazole may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild headache reported during therapy. - Diarrhea: loose stools or increased bowel movements. - Nausea: feeling of sickness or urge to vomit. - Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea with abdominal pain. - Low magnesium levels: muscle cramps, irregular heartbeat, or seizures.

Before prescribing Lansoprazole, clinicians should consider several safety considerations and patient‑specific factors. - Assess renal function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential interactions can affect efficacy or safety. - Monitor for infection: prolonged acid suppression may increase risk of gastrointestinal infections. - Evaluate bone health: long‑term use has been linked to decreased calcium absorption. - Use cautiously in pregnancy: safety data are limited; benefits should outweigh risks. - Store at room temperature: keep below 25°C in the original container, protect from moisture.

Lansoprazole can alter the pharmacokinetics of several drugs; awareness of these interactions helps optimize therapy.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir): reduced absorption, may compromise HIV treatment. - Antifungal agents (e.g., ketoconazole, itraconazole): decreased bioavailability, risking treatment failure. - Clopidogrel: reduced activation, potentially diminishing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation parameters. - Digoxin: higher serum levels may occur, observe for toxicity. - Methotrexate (high dose): reduced clearance, watch for toxicity.